BEST-CLI试验终点在三级医疗保肢项目中的相关性
单中心回顾性研究纳入2011至2021年连续469例因慢性肢体威胁性缺血行技术成功腹股沟下血运重建的患者,评估主要不良肢体事件无生存(MALE-FS)。中位随访189天时51%发生MALE或死亡,自体静脉旁路(AVB)独立提供最佳MALE-FS,血管内治疗(ENDO)后MALE更多为大截肢且转开放旁路较少。
要点
- 469例连续患者中,ENDO占57%、AVB占30%、非自体旁路(NAB)占13%。
- 调整后2年无MALE:AVB 72% vs ENDO 66% vs NAB 51%。
- ENDO后MALE更多为大截肢,仅6%的ENDO病例转为旁路。
核心结论
- 在该连续全来者队列中,疾病复杂性与手术方式选择和MALE-FS相关。
- AVB独立提供最高的MALE-FS以及无MALE和无大截肢生存。
- 与BEST-CLI随机试验相比,本系列ENDO后MALE更多为大截肢,转为开放旁路相对较少。
研究设计与样本
- 单中心回顾性研究,纳入2011至2021年连续、独特的因慢性肢体威胁性缺血行技术成功腹股沟下血运重建的患者。
- 共469例受试者,平均年龄70岁,34%为女性。
主要发现
- MALE或死亡复合终点发生于237例(51%),距指数血运重建中位时间189天。
- 调整Cox模型中,与MALE或死亡独立相关的因素包括较年轻年龄、终末期肾病(ESRD)、WIfI 4期、较高GLASS分期和中重度足部动脉钙化评分(pMAC),而AVB与改善的MALE-FS相关。
- 30天无MALE-FS、无MALE、无大截肢分别为90%、92%、95%;1年分别为63%、70%、83%。
- MALE发生于144例(31%),与ESRD、WIfI分期、GLASS分期、pMAC评分和指数血运重建方式相关;调整后2年无MALE:AVB 72% vs ENDO 66% vs NAB 51%。
- 在AVB组内,拼接静脉移植物相比单段静脉移植物MALE更高(风险比1.8;95%置信区间0.9-3.7;逆倾向加权后P=.008),但大截肢无统计学显著差异;144例MALE中首次MALE为大截肢占53%、大再干预占47%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Major adverse limb event-free survival (MALE-FS) differed significantly by initial revascularization approach in the BEST-CLI randomized trial. The BEST-CLI trial represented a highly selected subgroup of patients seen in clinical practice; thus, we examined the endpoint of MALE-FS in an all-comers tertiary care practice setting. METHODS: This is a single-center retrospective study of consecutive, unique patients who underwent technically successful infrainguinal revascularization for chronic limb-threatening ischemia (2011-2021). MALE was major amputation (transtibial or above) or major reintervention (new bypass, open bypass revision, thrombectomy, or thrombolysis). RESULTS: Among 469 subjects, the mean age was 70 years, and 34% were female. Characteristics included diabetes (68%), end-stage renal disease (ESRD) (16%), Wound, Ischemia, and foot Infection (WIfI) stage 4 (44%), Global Limb Anatomic Staging System (GLASS) stage 3 (62%), and high pedal artery calcium score (pMAC) (22%). Index revascularization was autogenous vein bypass (AVB) (30%), non-autogenous bypass (NAB) (13%), or endovascular (ENDO) (57%). The composite endpoint of MALE or death occurred in 237 patients (51%) at a median time of 189 days from index revascularization. In an adjusted Cox model, factors independently associated with MALE or death included younger age, ESRD, WIfI stage 4, higher GLASS stage, and moderate-severe pMAC, whereas AVB was associated with improved MALE-FS. Freedom from MALE-FS, MALE, and major amputation at 30 days were 90%, 92%, and 95%; and at 1 year were 63%, 70%, and 83%, respectively. MALE occurred in 144 patients (31%) and was associated with ESRD, WIfI stage, GLASS stage, pMAC score, and index revascularization approach. AVB had superior durability, with adjusted 2-year freedom from MALE of 72%, compared with 66% for ENDO and 51% for NAB. Within the AVB group, spliced vein conduit had higher MALE compared with single-segment vein (hazard ratio, 1.8; 95% confidence interval, 0.9-3.7; P = .008 after inverse propensity weighting), but there was no statistically significant difference in major amputation. Of the 144 patients with any MALE, the first MALE was major reintervention in 47% and major amputation in 53%. Major amputation as first MALE was associated with non-AVB index approach. Indications for major reintervention were symptomatic stenosis/occlusion (54%), lack of clinical improvement (28%), asymptomatic graft stenosis (16%), and iatrogenic events (3%). Conversion to bypass occurred after 6% of ENDO cases, two-thirds of which involved distal bypass targets at the ankle or foot. CONCLUSIONS: In this consecutive, all-comers cohort, disease complexity was associated with procedural selection and MALE-FS. AVB independently provided the greatest MALE-FS and freedom from MALE and major amputation. Compared with the BEST-CLI randomized trial, MALE after ENDO in this series was more frequently major amputation, with relatively few conversions to open bypass.
引用
- Liu IH, El Khoury R, Hiramoto JS, et al. Relevance of BEST-CLI trial endpoints in a tertiary care limb preservation program. J Vasc Surg. 2024. PMID: 38401777. doi:10.1016/j.jvs.2024.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。